Diamyd Medical announces completion of screening in pivotal Phase 3 DIAGNODE-3 trial

Diamyd Medical completed screening for its pivotal Phase 3 DIAGNODE-3 trial of retogatein (rhGAD65), expecting ~310–320 participants to be randomized with enrollment due by early March; the trial runs at 57 clinics across eight European countries and the U.S. Following an FDA Type C meeting, the company secured alignment to accelerate the primary efficacy readout from 24 to 15 months (and retains an interim analysis on ~170 participants due end-March 2026), a change that could bring primary efficacy data roughly nine months earlier and support an accelerated approval pathway. Retogatein holds FDA Fast Track and Orphan Drug designations for relevant stages of type 1 diabetes, and Diamyd is building a recombinant GAD65 manufacturing facility in Umeå, Sweden.

Analysis

Contrarian view: market optimism underestimates commercialization frictions — even a positive interim could be priced for perfection because full approval still requires durability; downside may be underpriced given small float and trial-specific genotype limitation. Historical parallel: teplizumab showed regulatory path but slow commercial uptake — expect similar adoption lags. Unintended consequence: accelerated readout may increase Type I error risk or leave payers demanding longer follow-up, compressing near-term valuation upside.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in Diamyd Medical (DMYD B) within 1–2 weeks to capture run-up to the interim efficacy analysis expected end-March 2026; size for high volatility and set a tactical stop-loss at -40% and scale out 50% of position on +100% or on positive interim disclosed p<0.05.
• If listed options exist, buy a 3–6 month call spread (bull call spread) sized to 1% portfolio risk OR buy the equity and purchase a protective put ~30% OTM expiring June 2026 to cap downside into the binary event; if no options, use position sizing above with a hard stop-loss.
• Implement a pair hedge: long DMYD B (2%) and short XBI (1%) or an equivalent small-cap biotech ETF to neutralize sector beta during the event window (enter within 2 weeks, rebalance at interim result).
• Avoid adding unhedged exposure to other experimental T1D immunotherapies; reduce generic small-cap biotech exposure by 1–2% and redeploy into event-driven single-stock trades. Monitor: enrollment completion (early March 2026), interim cohort size ≥170 with 15-month follow-up, and any FDA communications on statistical criteria — act within 48 hours of announced interim data.